Durvalumab increases overall survival in stage III non-small-cell lung cancer
The immune checkpoint inhibitor durvalumab significantly improves survival in people with stage III non-small-cell lung cancer, interim trial results published in The New England Journal of Medicine have shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer